Connection

Co-Authors

This is a "connection" page, showing publications co-authored by APAR PATAER and WAYNE L HOFSTETTER.
Connection Strength

0.947
  1. RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancer. Oncotarget. 2015 May 10; 6(13):11114-24.
    View in: PubMed
    Score: 0.132
  2. Insulin-like growth factor binding proteins increase intracellular calcium levels in two different cell lines. PLoS One. 2013; 8(3):e59323.
    View in: PubMed
    Score: 0.114
  3. The role of PKR/eIF2a signaling pathway in prognosis of non-small cell lung cancer. PLoS One. 2011; 6(11):e24855.
    View in: PubMed
    Score: 0.104
  4. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2024 Apr; 167(4):1444-1453.e4.
    View in: PubMed
    Score: 0.059
  5. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023 03; 29(3):593-604.
    View in: PubMed
    Score: 0.057
  6. Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022 11; 164(5):1327-1337.
    View in: PubMed
    Score: 0.053
  7. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
    View in: PubMed
    Score: 0.049
  8. Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. Eur J Cardiothorac Surg. 2021 01 04; 59(1):100-108.
    View in: PubMed
    Score: 0.049
  9. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. Clin Lung Cancer. 2020 07; 21(4):341-348.
    View in: PubMed
    Score: 0.046
  10. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice. Cancer. 2019 11 01; 125(21):3738-3748.
    View in: PubMed
    Score: 0.044
  11. Glutathione reductase (GSR) gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization. Am J Cancer Res. 2019; 9(6):1201-1211.
    View in: PubMed
    Score: 0.044
  12. Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. Ann Thorac Surg. 2018 Feb; 105(2):418-424.
    View in: PubMed
    Score: 0.040
  13. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett. 2015 Feb 01; 357(1):179-185.
    View in: PubMed
    Score: 0.032
  14. Insulin-like growth factor binding protein-2 level is increased in blood of lung cancer patients and associated with poor survival. PLoS One. 2013; 8(9):e74973.
    View in: PubMed
    Score: 0.030
  15. Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One. 2012; 7(2):e31087.
    View in: PubMed
    Score: 0.026
  16. KLF4 inhibition of lung cancer cell invasion by suppression of SPARC expression. Cancer Biol Ther. 2010 Apr 01; 9(7):507-13.
    View in: PubMed
    Score: 0.023
  17. Putative tumor-suppressive function of Kruppel-like factor 4 in primary lung carcinoma. Clin Cancer Res. 2009 Sep 15; 15(18):5688-95.
    View in: PubMed
    Score: 0.022
  18. Double-stranded RNA-dependent protein kinase-dependent apoptosis induction by a novel small compound. J Pharmacol Exp Ther. 2009 Mar; 328(3):866-72.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.